NuCana (NCNA)
(Delayed Data from NSDQ)
$3.40 USD
+0.04 (1.19%)
Updated Aug 13, 2024 03:49 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
NuCana PLC Sponsored ADR (NCNA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$150.00 | $150.00 | $150.00 | 4,311.76% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for NuCana PLC Sponsored ADR comes to $150.00. The forecasts range from a low of $150.00 to a high of $150.00. The average price target represents an increase of 4% from the last closing price of $3.40.
Analyst Price Targets (2 )
Broker Rating
NuCana PLC Sponsored ADR currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, three are Strong Buy, representing 75% of all recommendations. A month ago, Strong Buy represented 75%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/22/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/5/2024 | Cowen & Co. | Tara Bancroft | Hold | Hold |
3/21/2024 | William Blair | Matt Phipps | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 4 |
Average Target Price | $150.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 72 of 253 |
Current Quarter EPS Est: | -3.55 |